{
    "nctId": "NCT05266300",
    "briefTitle": "Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines.",
    "officialTitle": "Implementation and Quality Assurance of DPYD-genotyping in Patients Treated With Fluoropyrimidines",
    "overallStatus": "COMPLETED",
    "conditions": "Adverse Drug Event, Colon Cancer, Breast Cancer, Pancreas Cancer, Rectal Cancer, Gastric Cancer, Oesophageal Cancer, Bile Duct Cancer",
    "studyType": "OBSERVATIONAL",
    "phase": "N/A",
    "allocation": "N/A",
    "primaryPurpose": "N/A",
    "enrollmentCount": 722,
    "primaryOutcomeMeasure": "Adverse events",
    "eligibilityCriteria": "Inclusion Criteria:\n\n* Patients with cancer that are eligible for systemic treatment with 5-FU, capecitabine, or tegafur.\n\nExclusion Criteria:\n\n* Patients that earlier have been treated with 5-FU, capecitabine, or tegafur",
    "sex": "ALL",
    "minimumAge": "18 Years",
    "stdAges": "ADULT, OLDER_ADULT"
}